ProQR Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, ProQR Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

ProQR Therapeutics: 5 sponsored US clinical trials, none currently recruiting.

ProQR Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Vision Disorders, with 2 trials.

Upper-quartile sponsor footprint

ProQR Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

NCT04123626
ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

NCT03913143
COMPLETED Phase 1

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

NCT03780257
COMPLETED Phase 1

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

NCT02564354
COMPLETED Phase 1

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

NCT02532764

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Therapeutic Areas

Vision Disorders 2
Retinal Disease 2
Eye Diseases, Hereditary 2
Eye Diseases 2
Vision Tunnel 1
Retinitis 1
Autosomal Dominant Retinitis Pigmentosa 1
Retinal Dystrophies 1
Neurologic Manifestations 1
Eye Disorders Congenital 1

How the ProQR Therapeutics early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Vision Disorders (2 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

ProQR Therapeutics: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

ProQR Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share ProQR Therapeutics4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
ProQR Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ProQR Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ProQR Therapeutics page

5 registered trials is a research-attention snapshot, not an endorsement of ProQR Therapeutics or any single study.

  • None of ProQR Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Vision Disorders is the condition ProQR Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Vision Disorders trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ProQR Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.